Cadrenal Therapeutics (CVKD) Competitors $14.35 -0.15 (-1.03%) (As of 01:30 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CVKD vs. NVCT, ORMP, EPRX, ANVS, ASRT, IVVD, PWUP, QNCX, PYRGF, and GBIOShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Nuvectis Pharma (NVCT), Oramed Pharmaceuticals (ORMP), Eupraxia Pharmaceuticals (EPRX), Annovis Bio (ANVS), Assertio (ASRT), Invivyd (IVVD), PowerUp Acquisition (PWUP), Quince Therapeutics (QNCX), PyroGenesis Canada (PYRGF), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Nuvectis Pharma Oramed Pharmaceuticals Eupraxia Pharmaceuticals Annovis Bio Assertio Invivyd PowerUp Acquisition Quince Therapeutics PyroGenesis Canada Generation Bio Cadrenal Therapeutics (NASDAQ:CVKD) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation. Do analysts rate CVKD or NVCT? Cadrenal Therapeutics presently has a consensus price target of $18.00, suggesting a potential upside of 25.44%. Nuvectis Pharma has a consensus price target of $21.00, suggesting a potential upside of 325.96%. Given Nuvectis Pharma's higher possible upside, analysts clearly believe Nuvectis Pharma is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of CVKD or NVCT? 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 48.6% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 35.8% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to CVKD or NVCT? In the previous week, Nuvectis Pharma had 8 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 11 mentions for Nuvectis Pharma and 3 mentions for Cadrenal Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.41 beat Nuvectis Pharma's score of 0.41 indicating that Cadrenal Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvectis Pharma 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Neutral Which has more volatility and risk, CVKD or NVCT? Cadrenal Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Which has better earnings and valuation, CVKD or NVCT? Nuvectis Pharma is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadrenal TherapeuticsN/AN/A-$8.36M-$6.68-2.15Nuvectis PharmaN/AN/A-$22.26M-$1.16-4.25 Does the MarketBeat Community prefer CVKD or NVCT? Nuvectis Pharma received 3 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 90.00% of users gave Nuvectis Pharma an outperform vote. CompanyUnderperformOutperformCadrenal TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesNuvectis PharmaOutperform Votes990.00% Underperform Votes110.00% Is CVKD or NVCT more profitable? Cadrenal Therapeutics' return on equity of -142.95% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Cadrenal TherapeuticsN/A -142.95% -118.40% Nuvectis Pharma N/A -155.80%-104.02% SummaryCadrenal Therapeutics beats Nuvectis Pharma on 8 of the 14 factors compared between the two stocks. Ad Insiders Exposed917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.82M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-2.155.5095.1214.22Price / SalesN/A375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book6.9710.276.976.37Net Income-$8.36M$153.22M$118.73M$225.56M7 Day Performance-13.40%-1.19%-1.22%-0.02%1 Month Performance-5.84%-6.71%-3.07%2.04%1 Year PerformanceN/A32.39%32.52%28.00% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics1.683 of 5 stars$14.35-1.0%$18.00+25.4%N/A$23.82MN/A-2.154NVCTNuvectis Pharma3.3184 of 5 stars$4.93-2.8%$21.00+326.0%-38.8%$95.25MN/A-4.118ORMPOramed Pharmaceuticals1.478 of 5 stars$2.35+4.0%N/A+4.6%$94.73M$1.34M4.4310News CoverageEPRXEupraxia Pharmaceuticals2.4971 of 5 stars$3.46-3.9%$9.00+160.1%N/A$94.39MN/A-5.0329News CoverageGap DownANVSAnnovis Bio1.8748 of 5 stars$6.76+3.4%$32.17+375.8%+8.1%$93.29MN/A0.003ASRTAssertio3.2047 of 5 stars$0.95flat$3.25+242.1%-23.4%$90.71M$152.07M-1.3020Positive NewsIVVDInvivyd2.1459 of 5 stars$0.75-2.1%$7.52+899.6%-48.8%$89.95MN/A0.00100Analyst ForecastPWUPPowerUp AcquisitionN/A$11.50flatN/AN/A$89.36MN/A0.00N/AQNCXQuince Therapeutics2.508 of 5 stars$2.03+10.3%$8.50+318.7%+109.1%$89.32MN/A0.0060PYRGFPyroGenesis CanadaN/A$0.49-0.1%N/A+27.8%$89.26M$9.14M-8.0990News CoverageGBIOGeneration Bio3.3756 of 5 stars$1.32-2.2%$7.50+468.2%+7.1%$88.16M$5.90M0.00150Gap Up Related Companies and Tools Related Companies ORMP Competitors NVCT Competitors EPRX Competitors ANVS Competitors ASRT Competitors IVVD Competitors PWUP Competitors QNCX Competitors PYRGF Competitors GBIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CVKD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
